Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States

Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients

(2014) Alpesh Amin et al.   JOURNAL OF MEDICAL ECONOMICS

Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis

(2013) Sam Schulman et al.   CIRCULATION

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

(2013) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

All-cause and disease-related health care costs associated with recurrent venous thromboembolism

(2013) Patrick Lefebvre et al.   THROMBOSIS AND HAEMOSTASIS

Antithrombotic Therapy for VTE Disease

(2012) Clive Kearon et al.   CHEST

Pulmonary embolism and deep vein thrombosis

(2012) Samuel Z Goldhaber et al.   LANCET

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Venous thromboembolism: Annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates

(2012) Matthew E. Borrego et al.   THROMBOSIS AND HAEMOSTASIS

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study

(2009) Frederick A. Spencer et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

(2009) Sam Schulman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Epidemiology of Venous Thromboembolism in the Community

(2008) John A. Heit   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY